Purple Biotech Ltd.
PPBT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001614744
No open-market purchases or sales by Purple Biotech Ltd. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $141.0K in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Purple Biotech Ltd. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- +3 vs. Q3 2024
- Shares held
- 80.5K
- −89.9K (−52.8%) vs. Q3 2024
- Total value
- $377.9K
- −$568.2K (−60.1%) vs. Q3 2024
- New holders
- 6
- 2 more added
- Sold out
- 3
- 2 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PPBT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 13 | $141.0K |
| Q1 2026 | 15 | $305.6K |
| Q4 2025 | 19 | $513.2K |
| Q3 2025 | 16 | $75.9K |
| Q2 2025 | 14 | $133.7K |
| Q1 2025 | 9 | $134.3K |
| Q4 2024 | 14 | $377.9K |
| Q3 2024 | 11 | $946.1K |
| Q2 2024 | 21 | $775.9K |
| Q1 2024 | 21 | $1.77M |
| Q4 2023 | 20 | $1.90M |
| Q3 2023 | 18 | $275.9K |
| Q2 2023 | 17 | $388.3K |
| Q1 2023 | 16 | $224.2K |
| Q4 2022 | 15 | $238.6K |
| Q3 2022 | 11 | $224.0K |
| Q2 2022 | 14 | $310.2K |
| Q1 2022 | 14 | $1.77M |
| Q4 2021 | 13 | $4.09M |
| Q3 2021 | 12 | $5.27M |
| Q2 2021 | 13 | $3.72M |
| Q1 2021 | 15 | $2.40M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Purple Biotech Ltd.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| North Star Investment Management Corp. | 15 | $70 | 0.00% | 00.0% | Unchanged |
| Global Retirement Partners, LLC | 16 | $75 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 190 | $891 | 0.00% | +190 | New |
| TD Waterhouse Canada Inc. | 200 | $938 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 107 | $1.00K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 226 | $1.06K | 0.00% | −28−11.0% | Reduced |
| Crowley Wealth Management, Inc. | 300 | $1.41K | 0.00% | +300 | New |
| Rhumbline Advisers | 605 | $2.84K | 0.00% | +605 | New |
| Morgan Stanley | 5,115 | $24.0K | 0.00% | −2,940−36.5% | Reduced |
| BNP Paribas Arbitrage, SA | 5,375 | $25.2K | 0.00% | +1,700+46.3% | Added |
| Group One Trading, L.P. | 8,568 | $40.2K | 0.00% | +8,548+42,740.0% | Added |
| UBS Group AG | 10,783 | $50.6K | 0.00% | +10,783 | New |
| Two Sigma Securities, LLC | 15,374 | $72.1K | 0.01% | +15,374 | New |
| Kingswood Wealth Advisors, LLC | 33,594 | $157.6K | 0.01% | +33,594 | New |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −158,000−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −42−100.0% | Sold out |
| Danske Bank A/S | 0 | $0 | 0.00% | −4−100.0% | Sold out |